Dr. Feldman on Men With Prostate Cancer Receiving Treatment After Active Surveillance
Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses men with prostate cancer receiving treatment after active surveillance.
Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses men with prostate cancer receiving treatment after active surveillance.
In a study investigating active surveillance, pathologic progression was the main reason that men progressed to treatment, states Feldman. On a future biopsy, these men had an increased volume of disease or an increase of Gleason score.
Other reasons men progressed to treatment included a higher prostate-specific antigen (PSA) density, which correlates with higher volume of disease, explains Feldman.
